- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04382521
A Text Message Intervention to Promote Health Behaviors in Cardiac Risk Conditions
July 27, 2023 updated by: Jeff C. Huffman, MD, Massachusetts General Hospital
This is a randomized pilot trial to examine the feasibility, acceptability, and preliminary efficacy of an adaptive text message intervention (TMI) to promote well-being and health behavior adherence in 60 patients with two or more cardiac risk conditions (hypertension, type 2 diabetes, or hyperlipidemia).
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Detailed Description
The investigators have developed an adaptive text message intervention (TMI) that uses participant feedback for individual messages and progress towards health goals to deliver increasingly personalized positive psychology (PP) and health behavior text messages over time.
The investigators aim to examine its feasibility, acceptability, and preliminary efficacy in a randomized, controlled pilot trial in 60 adults with two or more cardiac risk conditions (hypertension, type 2 diabetes, or hyperlipidemia).
Study Type
Interventional
Enrollment (Actual)
69
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Massachusetts
-
Boston, Massachusetts, United States, 02114
- Massachusetts General Hospital
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Description
Inclusion Criteria:
- Cardiac risk conditions. Participants will have two or more of hypertension, type-2 diabetes, and hyperlipidemia. Patients will have met 2+ of 2017 AHA-ACC criteria for hypertension (SBP ≥130, DBP ≥80), 2018 ADA criteria for type-2 diabetes (e.g., A1C ≥6.5%), and 2013 AHA-ACC criteria for hyperlipidemia (e.g., LDL cholesterol ≥190), via medical record review, with confirmation by healthcare providers as needed.
- Low physical activity or elevated sedentary leisure time (SLT). Low activity will be defined as ≤150 minutes/week of moderate to vigorous activity (MVPA), which is an ADA-recommended level of MVPA; elevated SLT will be ≥120 min/day, which is linked to adverse medical health. As initial screens for both MVPA and SLT, we will use the International Physical Activity Questionnaire (IPAQ). Patients reporting ≤150 min/week of MVPA or ≥120 min/day of SLT will wear accelerometers for 10 days to confirm low MVPA/high SLT (patients will indicate their leisure time hours to allow assessment of SLT during those hours).
- Suboptimal diet. Participants must also report either fewer than 5 daily servings of fruit/vegetables (measured by the Behavioral Risk Factor Surveillance System's [BRFSS] Fruit and Vegetable Consumption Module) or have a score of ≥70 on the MEDFICTS scale for fat/cholesterol intake, representing high risk. We will require diet and activity deficits to ensure that a broad range of messages will be relevant to every participant as we explore the utility of individual messages and patterns of message selection in this initial study.
- Ability to receive text messages. Participants must have a cellular phone that receives texts and that they use at least daily. We will remunerate them the cost of receiving the messages as needed.
- Ability to read in English or Spanish. Text messages will be available in English and Spanish.
Exclusion Criteria:
- Existing coronary artery disease (CAD; diagnosed via cardiac catheterization using standard coronary artery stenosis definitions or prior ACS).
- An unrelated condition limiting physical activity.
- Participation in programs focused on cardiac prevention or well-being (e.g., cardiac rehabilitation).
- A cognitive disturbance precluding participation or informed consent, assessed using a six-item screen designed to assess suitability for research participation.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Single
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Text Message Intervention (TMI)
Participants in the TMI condition will receive daily text messages through an adaptive algorithm plus separate twice-weekly tailored messages focused on a specific health goal.
|
Participants will undergo a three component intervention consisting of (1) daily, adaptive text messages related to Positive Psychology or health behaviors, (2) twice weekly text messages related to a specific health behavior goal, and (3) three brief check-ins (at baseline, week 4, and week 8 of the intervention) with a study staff member to discuss progress towards health behavior goals.
During the brief check-ins, the study staff member will inquire about: (1) medical conditions, (2) adherence gaps, (3) personal health goals (including weight goals), (4) motivation, self-efficacy, and barriers to reaching health goals, (5) preferred activity types (e.g., walking), and (6) sources of sedentary time (e.g., computer, TV).
This information will be added to the algorithm for each individual and we will deliver tailored daily text messages for our participants.
|
Other: Wait-list Control Group (WLC)
Waitlist Control group participants will begin to receive the full 12-week Text Message Intervention (with all components, e.g., phone check-ins) after completing follow-up assessments at Weeks 12 and 24.
Participants in this group will receive no text messages or other study-specific interventions during the first 24 weeks of the study.
|
Participants will undergo a three component intervention consisting of (1) daily, adaptive text messages related to Positive Psychology or health behaviors, (2) twice weekly text messages related to a specific health behavior goal, and (3) three brief check-ins (at baseline, week 4, and week 8 of the intervention) with a study staff member to discuss progress towards health behavior goals.
During the brief check-ins, the study staff member will inquire about: (1) medical conditions, (2) adherence gaps, (3) personal health goals (including weight goals), (4) motivation, self-efficacy, and barriers to reaching health goals, (5) preferred activity types (e.g., walking), and (6) sources of sedentary time (e.g., computer, TV).
This information will be added to the algorithm for each individual and we will deliver tailored daily text messages for our participants.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Proportion of messages correctly delivered
Time Frame: 12 weeks
|
Proportion of adaptive TMI messages correctly selected/sent will be included as a measure of feasibility.
|
12 weeks
|
Rates of feedback to individual text messages
Time Frame: 12 weeks
|
Rates of feedback to individual text messages will be included as a measure of feasibility.
|
12 weeks
|
Participant's mean ratings of message utility to measure acceptability of the text-message intervention
Time Frame: 12 weeks
|
0-10 Likert scale score regarding the utility of that day's text message
|
12 weeks
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change in Positive and Negative Affect Schedule (PANAS) Score
Time Frame: Baseline, 12 weeks and 24 weeks
|
The positive affect items on the Positive and Negative Affect Schedule (PANAS), a well-validated scale used in other intervention trials and in patients with medical illnesses, will be used to measure positive affect.
(Range: 10-50).
Higher scores indicate higher levels of positive affect.
The measure will be used at baseline, 12 weeks and 24 weeks.
|
Baseline, 12 weeks and 24 weeks
|
Change in Life Orientation Test-Revised Score
Time Frame: Baseline, 12 weeks and 24 weeks
|
Life Orientation Test-Revised is a well-validated 6-item instrument used to measure dispositional optimism.
(Range: 0-24) Higher scores indicate higher levels of optimism.
The measure will be used at baseline, 12 weeks and 24 weeks.
|
Baseline, 12 weeks and 24 weeks
|
Change in General Self-Efficacy Scale score
Time Frame: Baseline, 12 weeks and 24 weeks
|
The General Self-Efficacy Scale is a self-report measure of self-efficacy.
The total score ranges from 10-40, with a higher score indicating more self-efficacy.
|
Baseline, 12 weeks and 24 weeks
|
Change in HADS-A Score
Time Frame: Baseline, 12 weeks and 24 weeks
|
The anxiety subscale of the Hospital Anxiety and Depression Scale (HADS-A) will be used to measure anxiety.
This is a well-validated scale with few somatic symptom items that can confound anxiety assessment in medically-ill patients.
(Range: 0-21) Higher scores indicate higher levels of anxiety.
The measure will be used at baseline, 12 weeks, and 24 weeks.
|
Baseline, 12 weeks and 24 weeks
|
Change in HADS-D Score
Time Frame: Baseline, 12 weeks and 24 weeks
|
The depression subscale of the Hospital Anxiety and Depression Scale (HADS-D) will be used to measure depression.
This is a well-validated scale with few somatic symptom items that can confound mood assessment in medically-ill patients.(Range:
0-21).
Higher scores indicate worse outcome (i.e.
greater levels of depression).
The measure will be used at baseline, 12 weeks, and 24 weeks.
|
Baseline, 12 weeks and 24 weeks
|
Change in Multidimensional Health Locus of Control Score
Time Frame: Baseline, 12 weeks and 24 weeks
|
This is an 18-item instrument that measures three dimensions of locus of control.
It assesses people's beliefs that their health is or is not determined by their own behavior.
The survey has three subscales: internality of health locus of control, powerful other locus of control, and chance locus of control.
All items are measured on a 6-point Likert scale, and our main subscale of interest will be internal locus of control, which will be a sum of scores from questions 1,6,8,12,13,17 (range: 6-36).
Higher scores indicate higher locus of control.
|
Baseline, 12 weeks and 24 weeks
|
Change in Multidimensional Scale of Perceived Social Support Score
Time Frame: Baseline, 12 weeks and 24 weeks
|
The MSPSS is a 12-item scale designed to measure perceived social support from three sources: Family, Friends, and a Significant Other.
It is rated on a 7-point likert scale, ranging from 1 "very strongly disagree" to 7 "very strongly agree."
Each subscale score can range from 4 to 28.
Items are summed, and a total score is also calculated and ranges from 12 to 84.
Higher subscale and total scores indicate high levels of perceived social support.
|
Baseline, 12 weeks and 24 weeks
|
Change in MEDFICTS score
Time Frame: Baseline, 12 weeks and 24 weeks
|
MEDFICTS is a screening instrument for dietary fat to assess adherence to the Adult Treatment Panel (ATP) III Therapeutic Lifestyle Changes (TLC) diet.
The test measures the intake of meats, eggs, dairy, fried foods, fats in baked goods, convenience foods, table fats, and snacks.
Higher scores indicate higher fat consumption.
|
Baseline, 12 weeks and 24 weeks
|
Change in Behavioral Risk Factor Surveillance System [BRFSS] Fruit and Vegetable Consumption Module
Time Frame: Baseline, 12 weeks and 24 weeks
|
The CDC's BRFSS Fruit and Vegetable Module is a brief questionnaire about frequency of eating different types of fruits and vegetables.
It assesses the frequency of consumption of 100% fruit juice, fruit, beans (legumes), dark green vegetables, orange vegetables, and other vegetables over the past month.
The outcome measure is the number of fruits or vegetables consumed per day.
|
Baseline, 12 weeks and 24 weeks
|
Change in Moderate to vigorous physical activity (minutes) measured via accelerometer
Time Frame: Baseline, 12 weeks and 24 weeks
|
Measured by Actigraph accelerometer, in minutes per day.
|
Baseline, 12 weeks and 24 weeks
|
Change in physical activity (steps) measured via accelerometer
Time Frame: Baseline, 12 weeks and 24 weeks
|
Measured by Actigraph accelerometer, in number of steps per day.
|
Baseline, 12 weeks and 24 weeks
|
Change in sedentary time measured via accelerometer
Time Frame: Baseline, 12 weeks and 24 weeks
|
Measured by Actigraph accelerometer, in minutes per day.
|
Baseline, 12 weeks and 24 weeks
|
Change in self-report physical activity time measured by International Physical Activity Questionnaire
Time Frame: Baseline, 12 weeks and 24 weeks
|
Measured by the self-report International Physical Activity Questionnaire (IPAQ).
The measure assess the types of intensity of physical activity that people do as part of their daily lives.
All activities are converted to multiples of resting energy expenditure (MET) minutes per week.
The measure will be used at baseline, 12 weeks, and 24 weeks.
|
Baseline, 12 weeks and 24 weeks
|
Change in physical function measured by PROMIS 20-item
Time Frame: Baseline, 12 weeks and 24 weeks
|
Measured by the 20-item short form of the Patient-Reported Outcomes Measurement Information System (PROMIS), a well-validated measure of physical function that is highly responsive to changes in a patient's physical function status (Range: 20-100).
Higher scores indicate better physical function.
|
Baseline, 12 weeks and 24 weeks
|
Change in physical function measured by 6-minute test
Time Frame: Baseline, 12 weeks and 24 weeks
|
The 6-minute walk test is a test to measure participant's functional capacity, assessing distance walked in meters in 6 minutes.
|
Baseline, 12 weeks and 24 weeks
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
September 22, 2020
Primary Completion (Actual)
April 15, 2023
Study Completion (Actual)
April 15, 2023
Study Registration Dates
First Submitted
April 25, 2020
First Submitted That Met QC Criteria
May 6, 2020
First Posted (Actual)
May 11, 2020
Study Record Updates
Last Update Posted (Actual)
July 28, 2023
Last Update Submitted That Met QC Criteria
July 27, 2023
Last Verified
July 1, 2023
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 2019P003495
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
NO
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Hypertension
-
National Taiwan University Hospital Hsin-Chu BranchRecruitingHypertension,Essential | Hypertension, MaskedTaiwan
-
University of Alabama at BirminghamTroy UniversityCompletedHypertension | Hypertension, Resistant to Conventional Therapy | Uncontrolled Hypertension | Hypertension, White CoatUnited States
-
BayerCompletedPrimary HypertensionChina
-
Columbia UniversityAgency for Healthcare Research and Quality (AHRQ)Active, not recruitingWhite Coat Hypertension | Hypertension,EssentialUnited States
-
Addpharma Inc.Completed
-
Universidade Federal de Santa MariaCompletedHealthy Volunteers | Hypertension, EssentialBrazil
-
Sheffield Teaching Hospitals NHS Foundation TrustUniversity of SheffieldCompletedIdiopathic Pulmonary Arterial Hypertension | Chronic Thromboembolic Pulmonary HypertensionUnited Kingdom
-
China Academy of Chinese Medical SciencesGuang'anmen Hospital of China Academy of Chinese Medical SciencesCompletedHypertension, Resistant to Conventional Therapy | Primary HypertensionChina
-
Cytos Biotechnology AGCompletedMild Essential Hypertension | Moderate Essential HypertensionSwitzerland
Clinical Trials on Text Message Intervention
-
University of PennsylvaniaCompletedGestational Diabetes | Diabetes in Pregnancy | Texting InterventionsUnited States
-
Jonsson Comprehensive Cancer CentereHealth International, INC.RecruitingObesity | Malignant NeoplasmUnited States
-
Samanta Winck MadrugaUnknown
-
Emory UniversityNational Cancer Institute (NCI)RecruitingMalignant Solid Neoplasm | Hematopoietic and Lymphoid System NeoplasmUnited States
-
Boston UniversityCompletedEating DisordersUnited States
-
City of Hope Medical CenterNational Cancer Institute (NCI)Active, not recruiting
-
Massachusetts General HospitalCompletedAcute Coronary SyndromeUnited States
-
University of PennsylvaniaCompletedColonoscopy | Adherence, Patient | Text MessagingUnited States
-
St. Louis UniversityEpharmix, Inc.TerminatedShort Bowel SyndromeUnited States
-
Boston Medical CenterCompletedAmbulation DifficultyUnited States